PA
RIGL icon

Parallel Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Parallel Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Sell
334
-6
-2% -$185 ﹤0.01% 2818
2026
Q1 		$9.19K Buy
340
+263
+342% +$8.84K ﹤0.01% 2790
2025
Q4 		$3.3K Buy
+77
New +$2.9K ﹤0.01% 2986
2022
Q2 		– Sell
-31
Closed -$1K – 3293
2022
Q1 		$1K Buy
31
+20
+182% +$541 ﹤0.01% 2820
2021
Q4 		$0 Buy
+11
New +$332 ﹤0.01% 3258

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's RIGL Position: Q2 2026 in Review

Parallel Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 1.8% in Q2 2026, selling an estimated $185 and leaving 334 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2818.

Parallel Advisors first reported a position in RIGL in Q4 2021 and has held it in 5 quarters since. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Parallel Advisors held 334 shares of Rigel Pharmaceuticals worth $13.1K as of Q2 2026.
  • Parallel Advisors sold 6 Rigel Pharmaceuticals shares in Q2 2026, an estimated $185.
  • Rigel Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2818 holding.
  • Parallel Advisors first reported a position in Rigel Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.